Blinklab Limited (AU:BB1) has released an update.
BlinkLab Limited has announced a key partnership with Dutch mental health service provider INTER-PSY to conduct a clinical trial for their AI-powered app designed to diagnose autism in children. This collaboration aims to refine the app’s algorithms and expedite regulatory approvals in the US and EU, addressing the urgent need for faster autism diagnostics, especially in females. The trial is a stepping stone towards an FDA 510(k) registration, signaling a potential breakthrough in reducing long wait times for autism diagnosis and treatment initiation.
For further insights into AU:BB1 stock, check out TipRanks’ Stock Analysis page.
